L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI

Psychoneuroendocrinology

Volumn 31, Issue 4, 2006, Pages 473-484

  Lowe, Stephen L ^a   Poo Yeo, Kwee ^a   Teng, Leyan ^a   Soon, Danny K W ^a   Pan, Alan ^a   Wise, Stephen D ^a   Peck, Richard W ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Augmentation; Citalopram; Cortisol; L 5 Hydroxytryptophan; Neuroendocrine; Prolactin

Indexed keywords

5 HYDROXYTRYPTOPHAN; CITALOPRAM; HYDROCORTISONE; PLACEBO; PROLACTIN; SEROTONIN UPTAKE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; MALE; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

5-HYDROXYTRYPTOPHAN; ADULT; AREA UNDER CURVE; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; NEUROSECRETORY SYSTEMS; PROLACTIN; REFERENCE VALUES; SEROTONIN UPTAKE INHIBITORS;

EID: 33644871228     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2005.11.005     Document Type: Article

References (57)

1. M. Asberg Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies Ann. NY Acad. Sci. 29 836 1997 158 181
2. M.J. Attenburrow, P.R. Mitter, R. Whale, T. Terao, and P.J. Cowen Low-dose citalopram as a 5-HT neuroendocrine probe Psychopharmacology 155 2001 323 326
3. T.A. Ban Pharmacotherapy of depression: a historical analysis J. Neural Transm. 108 2001 707 716
4. Z. Bhagwagar, S. Hafizi, and P.J. Cowen Acute citalopram administration produces correlated increases in plasma and salivary cortisol Psychopharmacology 163 2002 118 120
5. P. Blier The pharmacology of putative early-onset antidepressant strategies Eur. Neuropsychopharmacol. 13 2003 57 66
6. A. Broocks, N.C. Briggs, T.A. Pigott, J.L. Hill, S.K. Canter, T.J. Tolliver, D. Baldemore, and D.L. Murphy Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment Psychopharmacology 130 1997 91 103
7. D.S. Charney, G.R. Heninger, J.F. Reinhard Jr, D.E. Sternberg, and K. Hafstead The effect of intravenous l-tryptophan on prolactin and growth hormone and mood in healthy subjects Psychopharmacology 77 3 1982 217 222
8. P.J. Cowen Serotonin receptor subtypes in depression: evidence from studies in neuroendocrine regulation Clin. Neuropharmacol. 16 Suppl. 3 1993 S6 S18
9. P.J. Cowen Psychopharmacology of 5-HT1A receptors Nucl. Med. Biol. 27 2000 437 439
10. P.J. Cowen, S.L. McCance, M.G. Gelder, and D.G. Grahame-Smith Effect of amitriptyline on endocrine responses to intravenous l-tryptophan Psychiatry Res. 31 1990 201 208
11. J.F. Cryan, and B.E. Leonard 5-HT1A and beyond: the role of serotonin and its receptors in depression and the antidepressant response Hum. Psychopharmacol. Clin. Exp. 15 2 2000 113 135
12. J.F. Deakin Depression and antisocial personality disorder: two contrasting disorders of 5HT function J. Neural Transm. Suppl. 64 2003 79 93
13. C. DeBattista, M. Sofuoglu, and A.F. Schatzberg Serotonergic sunergism: the risks and benefits of combining the selective serotonin reuptake inhibitors with other serotonergic drugs Biol. Psychiatry 44 1998 314 347
14. T.G. Dinan Neuroendocrine markers. Role in the development of antidepressants CNS Drugs 10 2 1998 145 157
15. J.D. Flory, S.B. Manuck, and M.F. Muldoon Retest reliability of prolactin response to dl-fenfluramine challenge in adults Neuropsychopharmacology 26 2002 269 272
16. J.D. Flory, S.B. Manuck, J.M. Perel, and M.F. Muldoon A comparison of d,l-fenfluramine and citalopram challenges in healthy adults Psychopharmacology 174 2004 376 380
17. M.E. Freeman, B. Kanyicska, A. Lerant, and G. Nagy Prolactin: structure, function and regulation of secretion Physiol. Rev. 80 2000 1523 1631
18. K. Fuxe, L.L. Butcher, and J. Engel dl-5-hydroxytryptophan-induced changes in central monoamine neurons after peripheral decarboxylase inhibition J. Pharm. Pharmacol. 23 1971 420 424
19. H.J. Gijsman, J.M. van Gerven, M.L. de Kam, R.C. Schoemaker, M.S. Pieters, M. Weemaes, R. de Rijk, J. van der Post, and A.F. Cohen Placebo-controlled comparison of three dose-regimens of l-5-hydroxytryptophan challenge test in healthy volunteers J. Clin. Psychopharmacol. 22 2 2002 183 189
20. J.H. Gilmore, R.G. Ruegg, R.D. Ekstrom, B. Knight, S.W. Carson, G.A. Mason, and R.N. Golen Altered prolactin response to clomipramine rechallenge in healthy subjects Biol. Psychiatry 34 1993 885 888
21. R.N. Golden, J. Hsiao, E. Lane, R. Hicks, S. Rogers, and W.Z. Potter The effects of intravenous clomipramine on neurohormones in normal subjects J. Clin. Endocrinol. Metab. 68 3 1989 632 637
22. P.J. Goodnick, and B.J. Goldstein Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology J. Psychopharmacol. 12 1998 S5 S20
23. D. Gotjen, Z. Szabo, S. Lee, and G. Wand Hormone response to citalopram in abstinent alcohol dependent subjects Alcohol Clin. Exp. Res. 11 2002 1625 1631
24. J. Hennig, and P. Netter Oral application of citalopram (20 mg) and its usefulness for neuroendocrine challenge tests Int. J. Neuropsychopharmacol. 5 1 2002 67 71
25. C. Hiemke, and S. Härtter Pharmacokinetics of selective serotonin reuptake inhibitors Pharmacol. Ther. 85 2000 11 28
26. S. Hjorth, H.J. Bengtsson, A. Kullberg, D. Carlzon, H. Peilot, and S.B. Auerbach Serotonin autoreceptor function and antidepressant drug action J. Psychopharmacol. 14 2 2000 177 185
27. J. Hyttel Citalopram - a pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity Prog. Neuropsychopharmacol. Biol. Psychiatry 6 1982 277 295
28. O. Kalus, S. Wetzler, R.S. Kahn, G.M. Asnis, and H.M. van Praag A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects Psychopharmacology 106 1992 388 390
29. T. Kapitany, M. Schindl, S.D. Schindler, B. Heßelmann, T. Füreder, C. Barnas, W. Sieghart, and K. Siegfried The citalopram challenge test in patients with major depression and in healthy controls Psychiatry Res. 88 1999 75 88
30. Y. Kato, Y. Nakai, H. Imura, K. Chihara, and S. Ohgo Effects of l-5-hydroxytryptophan on plasma prolactin levels in man J. Clin. Endocrinol. 38 1974 695 697
31. H. Kojima, T. Terao, M. Iwakawa, A. Soya, N. Inoue, Y. Shiraishi, Y. Son, S. Soeda, N. Ueda, R. Yoshimura, and J. Nakamura Paroxetine as a 5-HT neuroendocrine probe Psychopharmacology 167 2003 97 102
32. A. Leake, A.F. Fairbairn, I.G. McKeith, and I.N. Ferrier Studies on the serotonin uptake binding site in major depressive disorder and control post-mortem brain: neurochemical and clinical correlates Psychiatry Res. 39 2 1991 155 165
33. M.A. Lee, J.F. Nash, M. Barnes, and H.Y. Meltzer Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans Psychopharmacology 103 1991 258 264
34. W. Lichtensteiger, U. Muntzmer, and H. Langermann Uptake of 5-hydroxytryptamine and 5-hydroxytryptophan by neurons of the central nervous system normally containing catecholamines J. Neurochem. 14 1967 489 497
35. P.S. Masand, and S. Gupta Selective serotonin-reuptake inhibitors: an update Harv. Rev. Psychiatry 7 2 1999 69 84
36. H.Y. Meltzer, and M. Maes Effect of pindolol on the l-5HTP-induced increase in plasma prolactin and cortisol concentrations in man Psychopharmacology 114 1994 635 643
37. H. Meltzer, B. Bastani, K. Jayathilake, and M. Maes Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder Neuropsychopharmacology 17 1997 1 11
38. H.S. Nadeem, M.J. Attenburrow, and P.J. Cowen Comparison of the effects of citalopram and escitalopram in 5-HT-mediated neuroendocrine responses Neuropsychopharmacology 29 2004 1699 1703
39. L.K.Y. Ng, T.N. Chase, R.W. Colburn, and I.J. Kopin Release of (3H) dopamine by l-5-hydroxytryptophan Brain Res. 45 1972 499 505
40. V. O'Keane, D. McLoughlin, and T.G. Dinan d-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment J. Affect. Disord. 26 1992 143 150
41. V. Pérez, D. Puigdemont, I. Gilaberte, E. Alvarez, and F. Artigas Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodolgic factors J. Clin. Psychopharmacol. 21 1 2001 36 45
42. R.J. Porter, R.H. McAllister-Williams, and A.H. Young Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers Psychopharmacology 146 1999 194 198
43. A.C. Power, and P.J. Cowen Neuroendocrine challenge tests: assessment of 5-HT function in anxiety and depression Mol. Aspects Med. 13 1992 205 220
44. L.H. Price, D.S. Charney, P.L. Delgado, G.M. Anderson, and G.R. Heninger Effects of desipramine and fluvoxamine treatment on the prolactin response to tryptophan. Serotonergic function and the mechanism of antidepressant action Arch. Gen. Psychiatry 46 1989 625 631
45. L.H. Price, D.S. Charney, P.L. Delgado, W.K. Goodman, J.H. Krystal, S.W. Woods, and G.R. Heninger Clinical data on the role of serotonin in the mechanism(s) of action of antidepressant drugs J. Clin. Psychiatry 51 Suppl. 4 1990 44 50
46. P.A. Sargent, D.J. Quested, and P.J. Cowen Clomipramine enhances the cortisol response to 5-HTP: implications for the therapeutic role of 5-HT2 receptors Psychopharmacology 140 1998 120 122
47. P.A. Sargent, K.H. Kjaer, C.J. Bench, E.A. Rabiner, C. Messa, J. Meyer, R.N. Gunn, P.M. Grasby, and P.J. Cowen Brain serotonin1A receptor binding measured by positron emission tomography with [11C] WAY-100635: effects of depression and antidepressant treatment Arch. Gen. Psychiatry 57 2 2000 174 180
48. K. Schruers, R. van Diest, N. Nicolson, and E. Griez l-5- Hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers Psychopharmacology 161 2002 365 369
49. E. Seifritz, P. Baumann, M.J. Muller, O. Annen, M. Amey, U. Hemmeter, M. Hatzinger, F. Chardon, and E. Holsboer-Trachsler Neuroendocrine effects of a 20-mg citalopram infusion in healthy males Neuropsychopharmacology 14 4 1996 253 263
50. B. Shapira, A. Reiss, N. Kaiser, S. Kindler, and B. Lerer Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients J. Affect. Disord. 16 1989 1 4
51. L. Sher, M.A. Oquendo, S.H. Li, S. Ellis, B.S. Brodsky, K.M. Malone, T.B. Cooper, and J.J. Mann Prolactin response to fenfluramine administration in patients with unipolar and bipolar depression and healthy controls Psychoneuroendocrinology 28 2003 559 573
52. S. Sobczak, A. Honig, M.A. van Duinen, and W.J. Riedel Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies Bipolar Disord. 4 2002 347 356
53. D.K. Sommers, W. van M, and J.R. Snyman Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine Eur. J. Clin. Pharmacol. 46 1994 441 444
54. 2A receptor status J. Clin. Psychopharmacol. 17 4 1997 292 297
55. L. Traskman, M. Asberg, L. Bertilsson, and L. Sjostrand Monoamine metabolites in CSF and suicidal behavior Arch. Gen. Psychiatry 38 6 1981 631 636
56. I.M. van Vliet, B.R. Slaap, H.G.M. Westenberg, and J.A. den Boer Behavioral, neuroendocrine and biochemical effects of different doses of 5-HTP in panic disorder Eur. J. Neuropsychopharmacol. 6 1996 103 110
57. T.E. Weltzin, C. McConaha, M. McKee, L.K.G. Hsu, J. Perel, and H.K. Walter Circadian patterns of cortisol, prolactin, and growth hormonal secretion during bingeing and vomiting in normal weight bulimic patients Biol. Psychiatry 30 1991 37 48